CorVel
CRVL · Health Care Services
$83.87
0.0%Tempus AI
TEM · Health Care Services
$67.62
6.0%The short version
- Tempus AI is the larger business, with $1.3B of revenue in fiscal 2025 against $959M for CorVel.
- Tempus AI grew revenue faster (83.4%, against 7.0%).
- CorVel turned more of its sales into free cash flow (11.5% FCF margin, against −18.8% FCF margin).
| Latest fiscal year | CRVL · FY26 | TEM · FY25 |
|---|---|---|
| Size | ||
| Market cap | $4.3B | $13.5M |
| Revenue | $959M | $1.3B |
| Free cash flow | $110M | −$239M |
| Net income | $110M | −$245M |
| Growth | ||
| Revenue growth | 7.0% | 83.4% |
| 5-year growth | 11.6% | — |
| Share count change | −0.7% | 45.4% |
| Profitability | ||
| Gross margin | 24.3% | — |
| Operating margin | — | −19.9% |
| Net margin | 11.5% | −19.3% |
| FCF margin | 11.5% | −18.8% |
| Return on capital | — | — |
| Return on equity | 30.8% | −89.5% |
| Balance sheet | ||
| Net debt | — | −$396M |
| Net debt / EBITDA | — | — |
| Dividends and buybacks | $56.2M | $3.0M |
| Valuation & quality | ||
| P/E | 37.3x | — |
| Piotroski F-score | — | 5 |
FY17
CRVL $519M
TEM —
FY18
CRVL $558M
TEM —
FY19
CRVL $596M
TEM —
FY20
CRVL $592M
TEM —
FY21
CRVL $553M
TEM —
FY22
CRVL $646M
TEM $321M
FY23
CRVL $719M
TEM $532M
FY24
CRVL $795M
TEM $693M
FY25
CRVL $896M
TEM $1.3B
FY26
CRVL $959M
TEM —
CRVL
TEM
FY17
CRVL —
TEM —
FY18
CRVL —
TEM —
FY19
CRVL —
TEM —
FY20
CRVL —
TEM —
FY21
CRVL —
TEM —
FY22
CRVL —
TEM −82.8%
FY23
CRVL —
TEM −36.9%
FY24
CRVL —
TEM −99.7%
FY25
CRVL —
TEM −19.9%
FY26
CRVL —
TEM —
CRVL
TEM
FY17
CRVL $21.0M
TEM —
FY18
CRVL $34.5M
TEM —
FY19
CRVL $63.4M
TEM —
FY20
CRVL $48.5M
TEM —
FY21
CRVL $77.1M
TEM —
FY22
CRVL $37.4M
TEM −$187M
FY23
CRVL $56.0M
TEM −$249M
FY24
CRVL $70.0M
TEM −$211M
FY25
CRVL $91.6M
TEM −$239M
FY26
CRVL $110M
TEM —
CRVL
TEM
FY17
CRVL —
TEM —
FY18
CRVL —
TEM —
FY19
CRVL —
TEM —
FY20
CRVL —
TEM —
FY21
CRVL —
TEM —
FY22
CRVL —
TEM —
FY23
CRVL —
TEM —
FY24
CRVL —
TEM —
FY25
CRVL —
TEM —
FY26
CRVL —
TEM —
CRVL
TEM
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.